<?xml version="1.0" encoding="UTF-8"?>
<iati-activities>
 <iati-activity default-currency="CAD" dstore:dataset="idrccrdi-act-2016-6" dstore:index="239" hierarchy="1" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore">
  <iati-identifier>XM-DAC-301-2-109548-001</iati-identifier>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Broad-spectrum antiviral nasal sprays to prevent infection by SARS-CoV2 and seasonal respiratory viruses in patients and healthcare providers</narrative>
   <narrative xml:lang="FR">Vaporisateurs nasaux antiviraux &#xE0; large spectre pour pr&#xE9;venir l&#x2019;infection par le SRAS-CoV-2 et les virus respiratoires saisonniers</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">In March 2020, the World Health Organization declared a pandemic due to the emergence of a novel coronavirus (SARS-CoV2) which causes COVID-19, a potentially lethal respiratory infection. There are currently no antiviral agents to prevent or treat SARS-CoV2 infections. This project proposes the optimization and prototype development of a broad spectrum antiviral pharmaceutical preparation (RespVirex) to protect healthcare workers and high-risk patients from SARS-CoV2 and dozens of other seasonal and pandemic viruses. 

The team aims to deliver RespVirex by nasal spray and nebulized aerosol. A nasal spray can be dosed conveniently by healthcare workers as needed during respiratory virus seasons or a pandemic. RespVirex can also be inhaled by nebulizer to treat the lower respiratory tract. The pharmaceutical formulation of the nasal spray and nebulized aerosol will be developed in Canada, while its ability to inhibit SARS-CoV2 and other respiratory viruses will be evaluated at the Institut Pasteur in Dakar, Senegal.

The project was selected for funding through the COVID-19 May 2020 Rapid Research Funding Opportunity, coordinated by the Canadian Institutes of Health Research in partnership with IDRC and several other health research funding agencies across Canada.</narrative>
   <narrative xml:lang="FR">En mars 2020, l&#x2019;Organisation mondiale de la Sant&#xE9; a d&#xE9;clar&#xE9; une pand&#xE9;mie due &#xE0; l&#x2019;&#xE9;mergence d&#x2019;un nouveau coronavirus (SRAS-CoV-2) qui provoque la COVID-19, une infection respiratoire potentiellement mortelle. Il n&#x2019;existe actuellement aucun agent antiviral pour pr&#xE9;venir ou traiter les infections par le SRAS-CoV2. Ce projet propose l&#x2019;optimisation et le prototypage d&#x2019;une pr&#xE9;paration pharmaceutique antivirale &#xE0; large spectre (RespVirex) pour prot&#xE9;ger les travailleurs de la sant&#xE9; et les patients &#xE0; haut risque contre le SRAS-CoV-2 et des dizaines d&#x2019;autres virus saisonniers et pand&#xE9;miques. 

L&#x2019;&#xE9;quipe vise &#xE0; administrer la pr&#xE9;paration RespVirex par vaporisateur nasal et par a&#xE9;rosol n&#xE9;bulis&#xE9;. Un vaporisateur nasal peut &#xEA;tre dos&#xE9; de mani&#xE8;re pratique par les travailleurs de la sant&#xE9; en fonction des besoins pendant les saisons des virus respiratoires ou une pand&#xE9;mie. La pr&#xE9;paration RespVirex peut &#xE9;galement &#xEA;tre inhal&#xE9;e par n&#xE9;buliseur pour traiter les voies respiratoires inf&#xE9;rieures. La formulation pharmaceutique du vaporisateur nasal et de l&#x2019;a&#xE9;rosol n&#xE9;bulis&#xE9; sera &#xE9;labor&#xE9;e au Canada, tandis que sa capacit&#xE9; &#xE0; inhiber le SRAS-CoV2 et d&#x2019;autres virus respiratoires sera &#xE9;valu&#xE9;e &#xE0; l&#x2019;Institut Pasteur de Dakar, au S&#xE9;n&#xE9;gal.

Le projet a &#xE9;t&#xE9; s&#xE9;lectionn&#xE9; pour un financement dans le cadre de la Possibilit&#xE9; de financement pour une intervention de recherche rapide relative &#xE0; la COVID-19 en mai 2020, coordonn&#xE9; par les Instituts de recherche en sant&#xE9; du Canada en partenariat avec le CRDI et plusieurs autres organismes de financement de la recherche en sant&#xE9; au Canada.</narrative>
  </description>
  <participating-org role="4" type="11">
   <narrative xml:lang="EN">The Governors of the University of Alberta</narrative>
  </participating-org>
  <participating-org role="2" type="11">
   <narrative xml:lang="EN">The Governors of the University of Alberta</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Canada. Parliament</narrative>
   <narrative xml:lang="FR">Canada. Parlement</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2020-08-01" type="2"></activity-date>
  <activity-date iso-date="2021-08-01" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <email>info@idrc.ca</email>
   <website>http://www.idrc.ca</website>
   <mailing-address>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
  </contact-info>
  <activity-scope code="2"></activity-scope>
  <recipient-country code="SN" percentage="35"></recipient-country>
  <recipient-region code="389" percentage="65" vocabulary="1"></recipient-region>
  <sector percentage="100" vocabulary="1"></sector>
  <sector code="1" percentage="100" vocabulary="99">
   <narrative xml:lang="EN">Other</narrative>
   <narrative xml:lang="FR">Autre</narrative>
  </sector>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-08-31"></transaction-date>
   <value currency="CAD" value-date="2020-08-31">629356</value>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">The Governors of the University of Alberta</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-08-31"></transaction-date>
   <value currency="CAD" value-date="2020-08-31">-629356</value>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">The Governors of the University of Alberta</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2020-08-25"></transaction-date>
   <value currency="CAD" value-date="2020-08-25">629356</value>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">The Governors of the University of Alberta</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-08-25"></transaction-date>
   <value currency="CAD" value-date="2020-08-25">662480</value>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">The Governors of the University of Alberta</narrative>
   </receiver-org>
   <disbursement-channel code="2"></disbursement-channel>
  </transaction>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Grant is conditional on completion of specified terms of reference, receipt of specified deliverables</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de respecter le mandat &#xE9;tabli et de livrer les r&#xE9;sultats attendus</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de p&#xE9;riodiquement pr&#xE9;senter une justification d&#xE9;taill&#xE9;e de l&apos;utilisation des fonds vers&#xE9;s par le CRDI ainsi qu&apos;une estimation budg&#xE9;taire de la p&#xE9;riode de rapport suivante</narrative>
   </condition>
  </conditions>
 </iati-activity>
</iati-activities>
